India Pharma Outlook Team | Monday, 05 May 2025
Indian Contract Development and Manufacturing Organisations (CDMOs) like Suven Pharmaceuticals, Syngene International, Laurus Labs, and Divi’s Laboratories are witnessing a surge in demand as global pharma players seek to reduce dependence on China. Geopolitical tensions, supply chain vulnerabilities, and looming trade regulations—especially the proposed US Biosecure Act—are accelerating the “China plus one” strategy, making India an attractive alternative.
Suven Pharmaceuticals, with the support of Advent International, sees a sharp increase in strategic talks and co-investment offers from US and European pharmaceutical firms. Chairman Vivek Sharma points towards increased interest, specifically in advanced capabilities such as antibody-drug conjugates (ADCs), peptides, and oligonucleotides. Suven aims for $1 billion in revenues by 2030 and is expanding its US operations and offering high-value services.
Syngene International is also taking advantage of this transition. The company has experienced a consistent conversion of pilot programs to full-scale contracts as international pharma companies diversify their supply chains. To further solidify its position, Syngene has purchased a US-based biologics manufacturing facility, providing clients with improved supply security. It expects double-digit revenue growth in FY26, backed by a strong and diversified portfolio.
Laurus Labs is moving away from its core antiretroviral API focus to build its CDMO business. Its small molecule CDMO business grew 49% in FY25, supported by more than 110 active projects and heavy investment in new technologies such as flow chemistry and biocatalysis. A planned Rs 1,000 crore capex in FY26 will further support this shift, including doubling its fermentation capacity.
Meanwhile, Divi’s Laboratories has inked a long-term deal with a global pharma major for advanced intermediates and announced a Rs 650-700 crore investment in expanding its custom synthesis operations.
, CDSCO.jpg)
